null

SMILES: CC(C)c1cc(NC(=O)Nc2ccc(Oc3ccnc(Nc4ccccc4)c3)c3ccccc23)n(n1)-c1cccc(CP(C)(C)=O)c1

InChI Key: InChIKey=KVPNQKXHQVOBDL-UHFFFAOYSA-N

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 3 hits for monomerid = 354314   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kcal/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
Proto-oncogene tyrosine-protein kinase Src (Homo sapiens (Human))	BDBM354314 (1-(1-(3-((Dimethylphosphoryl)methyl)phenyl)-3-isop...) Show SMILES CC(C)c1cc(NC(=O)Nc2ccc(Oc3ccnc(Nc4ccccc4)c3)c3ccccc23)n(n1)-c1cccc(CP(C)(C)=O)c1 Show InChI InChI=1S/C37H37N6O3P/c1-25(2)33-23-36(43(42-33)28-14-10-11-26(21-28)24-47(3,4)45)41-37(44)40-32-17-18-34(31-16-9-8-15-30(31)32)46-29-19-20-38-35(22-29)39-27-12-6-5-7-13-27/h5-23,25H,24H2,1-4H3,(H,38,39)(H2,40,41,44)	PDB MMDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	47	n/a	n/a	n/a	n/a	n/a	n/a
Respivert Limited; Topivert Pharma Limited US Patent					Assay Description The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashion to that descri...				US Patent US9796742 (2017) BindingDB Entry DOI: 10.7270/Q2KW5J5M
					More data for this Ligand-Target Pair
Glycogen synthase kinase-3 alpha (Homo sapiens (Human))	BDBM354314 (1-(1-(3-((Dimethylphosphoryl)methyl)phenyl)-3-isop...) Show SMILES CC(C)c1cc(NC(=O)Nc2ccc(Oc3ccnc(Nc4ccccc4)c3)c3ccccc23)n(n1)-c1cccc(CP(C)(C)=O)c1 Show InChI InChI=1S/C37H37N6O3P/c1-25(2)33-23-36(43(42-33)28-14-10-11-26(21-28)24-47(3,4)45)41-37(44)40-32-17-18-34(31-16-9-8-15-30(31)32)46-29-19-20-38-35(22-29)39-27-12-6-5-7-13-27/h5-23,25H,24H2,1-4H3,(H,38,39)(H2,40,41,44)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	6.98E+3	n/a	n/a	n/a	n/a	n/a	n/a
Respivert Limited; Topivert Pharma Limited US Patent					Assay Description The inhibitory activities of compounds of the invention against the GSK 3?? enzyme isoform (Invitrogen), are evaluated by determining the level of ac...				US Patent US9796742 (2017) BindingDB Entry DOI: 10.7270/Q2KW5J5M
					More data for this Ligand-Target Pair
Tyrosine-protein kinase SYK (Homo sapiens (Human))	BDBM354314 (1-(1-(3-((Dimethylphosphoryl)methyl)phenyl)-3-isop...) Show SMILES CC(C)c1cc(NC(=O)Nc2ccc(Oc3ccnc(Nc4ccccc4)c3)c3ccccc23)n(n1)-c1cccc(CP(C)(C)=O)c1 Show InChI InChI=1S/C37H37N6O3P/c1-25(2)33-23-36(43(42-33)28-14-10-11-26(21-28)24-47(3,4)45)41-37(44)40-32-17-18-34(31-16-9-8-15-30(31)32)46-29-19-20-38-35(22-29)39-27-12-6-5-7-13-27/h5-23,25H,24H2,1-4H3,(H,38,39)(H2,40,41,44)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	63	n/a	n/a	n/a	n/a	n/a	n/a
Respivert Limited; Topivert Pharma Limited US Patent					Assay Description The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...				US Patent US9796742 (2017) BindingDB Entry DOI: 10.7270/Q2KW5J5M
					More data for this Ligand-Target Pair